Analyst consensus rating
Dianthus Therapeutics Analyst Rating: Strong Buy
Direct answer
Dianthus Therapeutics's consensus rating is Strong Buy.
16 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $139.06.
Forecast evidence checked November 1, 2026.
Get free Dianthus Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $82.38
- Average price target
- $139.06
- High price target
- $200.00
- Low price target
- $113.00
- Low target gap
- +37.2%
- Target upside
- +68.8%
- High target gap
- +142.8%
- Target range width
- 105.6%
- Consensus rating
- Strong Buy
- Analysts
- 16
- Evidence date
- November 1, 2026
- Valid through
- November 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Dianthus Therapeutics?
Dianthus Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $139.06.
How far are Dianthus Therapeutics's low and high targets from the recorded price?
The low target implies +37.2%, while the high target implies +142.8%.
How many analysts are included in Dianthus Therapeutics's consensus?
The verified consensus includes 16 analysts.
How is Dianthus Therapeutics's target upside or downside calculated?
The average target of $139.06 is divided by the recorded price of $82.38, then one is subtracted to produce +68.8%. This does not guarantee a future return.
When was Dianthus Therapeutics's analyst forecast verified?
The data was verified on 2026-11-01. The dataset is valid through 2026-11-08.